Intended Audience:
This symposium is designed for interventional cardiologists, cardiologists, emergency physicians, program directors, and other healthcare providers caring for patients with acute cardiovascular disease.
Registration:
Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified symposium and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support:
Supported by an independent educational grant from The Medicines Company, Inc.
Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Faculty Disclosures:
C. Michael Gibson, MS, MD, FACC
Grant/Research Support: CardioKinetix, Eli Lily, KAI Pharmaceuticals, Nuvelo, Schering-Plough, sanofi-aventis, St. June Medical, Baxter, Novartis, FoldRx, INO TherapeuticsConsultant: Angel Medical Systems, The Medicines Co., HeartScape Technologies, Archemix, PDL Pharmaceuticals, Atrium Medical, Timi3 Systems, Biogen IDEC
Speaker’s Bureau: Genentech, GSK, Schering-Plough, The Medicines Co.
Frederick Feit, MD, FACC
Consultant: The Medicines Co.
Major Shareholder: Johnson & Johnson, Millennium Pharmaceuticals, The Medicines Co.
Charles V. Pollack, MD, FACEP, FAAEM
Grant/Research Support: GlaxoSmithKlineConsultant: The Medicines Co., Schering-Plough, sanofi-aventis, BMS, GenentechSpeaker’s Bureau: Schering-Plough, sanofi-aventis, BMS, Genentech
Faculty:
C. Michael Gibson, MS, MD, FACC
Director TIMI Data Coordinating Center
Associate Professor
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, MA
Frederick Feit, MD, FACC
Director, Cardiac Catheterization and
Interventional Cardiology
Bellevue Hospital Center
Associate Professor of Medicine
New York University School of Medicine
New York, NY
Charles V. Pollack, MD, FACEP, FAAEM
Chairman, Department of Emergency Medicine
Pennsylvania Hospital
Professor of Emergency Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA
Educational Objectives:
• As a result of this session, cardiologists and emergency physicians will be able to assess and implement optimal antithrombotic strategies for patients with acute coronary syndromes (ACS).
• As a result of this session, attendees will understand impact of specific pharmacologic agents on outcomes, including ischemic endpoints, bleeding, and mortality for patients with ACS.
• As a result of this session, attendees are able to discuss the impact that new trials are likely to have on future management of patients with ACS.
• As a result of this session, ED physicians and cardiologists will learn to apply AHA/ACC, ACCP, and other national guidelines in order to optimize therapy ACS.
|
